_id
69105616ccc777a4e85d5605
Ticker
CSTL
Name
Castle Biosciences Inc
Exchange
NASDAQ
Address
505 S. Friendswood Drive, Friendswood, TX, United States, 77546
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://castlebiosciences.com
Description
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Last Close
37.97
Volume
156298
Current Price
38.47
Change
1.316829075585989
Last Updated
2025-11-29T11:55:56.161Z
Image
data:image/webp;base64,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
Ipo Date
2019-07-25T00:00:00.000Z
Market Cap
1166087040
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9956000000000002
Sentiment Sources
15
Rating
4.8889
Target Price
37.25
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
83043000
Cost Of Revenue
18704000
Gross Profit
64339000
Operating Expenses
71143000
Operating Income
-6804000
Interest Expense
24000
Pretax Income
-386000
Net Income
-501000
Eps
-0.017232483747807243
Dividends Per Share
-
Shares Outstanding
29188659
Income Tax Expense
115000
EBITDA
5245328
Operating Margin
-8.193345616126585
Total Other Income Expense Net
6418000
Cash
85556000
Short Term Investments
201986000
Receivables
49482000
Inventories
8650000
Total Current Assets
357569000
Property Plant Equipment
100036000
Total Assets
562786000
Payables
12211000
Short Term Debt
1449000
Long Term Debt
10049000
Total Liabilities
95740000
Equity
467046000
Depreciation
3816000
Change In Working Capital
11503000
Cash From Operations
22631000
Capital Expenditures
14834000
Cash From Investing
-18389000
Cash From Financing
-919000
Net Change In Cash
3323000
PE
-
PB
2.394706966765586
ROE
-0.10726994771392967
ROA
-0.08902140422825017
FCF
7797000
Fcf Percent
0.09389111665041003
Piotroski FScore
2
Health Score
43
Deep Value Investing Score
5
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
6.8
Garp Investing Score
4
Growth Investing Score
3
Momentum Investing Score
6
Net Net Investing Score
2.5
Quality Investing Score
4.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
83043000
Quarters > 0 > income Statement > cost Of Revenue
18704000
Quarters > 0 > income Statement > gross Profit
64339000
Quarters > 0 > income Statement > operating Expenses
71143000
Quarters > 0 > income Statement > operating Income
-6804000
Quarters > 0 > income Statement > interest Expense
24000
Quarters > 0 > income Statement > pretax Income
-386000
Quarters > 0 > income Statement > net Income
-501000
Quarters > 0 > income Statement > eps
-0.017232483747807243
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
29073000
Quarters > 0 > income Statement > income Tax Expense
115000
Quarters > 0 > income Statement > EBITDA
5245328
Quarters > 0 > income Statement > operating Margin
-8.193345616126585
Quarters > 0 > income Statement > total Other Income Expense Net
6418000
Quarters > 0 > balance Sheet > cash
85556000
Quarters > 0 > balance Sheet > short Term Investments
201986000
Quarters > 0 > balance Sheet > receivables
49482000
Quarters > 0 > balance Sheet > inventories
8650000
Quarters > 0 > balance Sheet > total Current Assets
357569000
Quarters > 0 > balance Sheet > property Plant Equipment
100036000
Quarters > 0 > balance Sheet > total Assets
562786000
Quarters > 0 > balance Sheet > payables
12211000
Quarters > 0 > balance Sheet > short Term Debt
1449000
Quarters > 0 > balance Sheet > long Term Debt
10049000
Quarters > 0 > balance Sheet > total Liabilities
95740000
Quarters > 0 > balance Sheet > equity
467046000
Quarters > 0 > cash Flow > net Income
-501000
Quarters > 0 > cash Flow > depreciation
3816000
Quarters > 0 > cash Flow > change In Working Capital
11503000
Quarters > 0 > cash Flow > cash From Operations
22631000
Quarters > 0 > cash Flow > capital Expenditures
14834000
Quarters > 0 > cash Flow > cash From Investing
-18389000
Quarters > 0 > cash Flow > cash From Financing
-919000
Quarters > 0 > cash Flow > net Change In Cash
3323000
Quarters > 0 > ratios > PE
-0.017232483747807243
Quarters > 0 > ratios > PB
2.394706966765586
Quarters > 0 > ratios > ROE
-0.10726994771392967
Quarters > 0 > ratios > ROA
-0.08902140422825017
Quarters > 0 > ratios > FCF
7797000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.09389111665041003
Quarters > 0 > health Score
43
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
86188000
Quarters > 1 > income Statement > cost Of Revenue
17626000
Quarters > 1 > income Statement > gross Profit
68562000
Quarters > 1 > income Statement > operating Expenses
72813000
Quarters > 1 > income Statement > operating Income
-4251000
Quarters > 1 > income Statement > interest Expense
21000
Quarters > 1 > income Statement > pretax Income
-143000
Quarters > 1 > income Statement > net Income
4523000
Quarters > 1 > income Statement > eps
0.15308850905398544
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
29545000
Quarters > 1 > income Statement > income Tax Expense
-4666000
Quarters > 1 > income Statement > EBITDA
3292000
Quarters > 1 > income Statement > operating Margin
-4.93224114725948
Quarters > 1 > income Statement > total Other Income Expense Net
4108000
Quarters > 1 > balance Sheet > cash
82233000
Quarters > 1 > balance Sheet > short Term Investments
193697000
Quarters > 1 > balance Sheet > receivables
52311000
Quarters > 1 > balance Sheet > inventories
8366000
Quarters > 1 > balance Sheet > total Current Assets
348668000
Quarters > 1 > balance Sheet > property Plant Equipment
89563000
Quarters > 1 > balance Sheet > total Assets
544729000
Quarters > 1 > balance Sheet > payables
13181000
Quarters > 1 > balance Sheet > short Term Debt
3515000
Quarters > 1 > balance Sheet > long Term Debt
8096000
Quarters > 1 > balance Sheet > total Liabilities
89353000
Quarters > 1 > balance Sheet > equity
455376000
Quarters > 1 > cash Flow > net Income
4523000
Quarters > 1 > cash Flow > depreciation
3414000
Quarters > 1 > cash Flow > change In Working Capital
8510000
Quarters > 1 > cash Flow > cash From Operations
20821000
Quarters > 1 > cash Flow > capital Expenditures
9263000
Quarters > 1 > cash Flow > cash From Investing
-28378000
Quarters > 1 > cash Flow > cash From Financing
101000
Quarters > 1 > cash Flow > net Change In Cash
-7456000
Quarters > 1 > ratios > PE
0.15308850905398544
Quarters > 1 > ratios > PB
2.495950928463511
Quarters > 1 > ratios > ROE
0.9932451424756685
Quarters > 1 > ratios > ROA
0.8303211321592939
Quarters > 1 > ratios > FCF
11558000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.1341021952011881
Quarters > 1 > health Score
64
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
87988000
Quarters > 2 > income Statement > cost Of Revenue
16383000
Quarters > 2 > income Statement > gross Profit
71605000
Quarters > 2 > income Statement > operating Expenses
99533000
Quarters > 2 > income Statement > operating Income
-27928000
Quarters > 2 > income Statement > interest Expense
17000
Quarters > 2 > income Statement > pretax Income
-26271000
Quarters > 2 > income Statement > net Income
-25848000
Quarters > 2 > income Statement > eps
-0.9034919081407948
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
28609000
Quarters > 2 > income Statement > income Tax Expense
-423000
Quarters > 2 > income Statement > EBITDA
3510000
Quarters > 2 > income Statement > operating Margin
-31.740691912533524
Quarters > 2 > income Statement > total Other Income Expense Net
1657000
Quarters > 2 > balance Sheet > cash
89689000
Quarters > 2 > balance Sheet > short Term Investments
185462000
Quarters > 2 > balance Sheet > receivables
56353000
Quarters > 2 > balance Sheet > inventories
6849000
Quarters > 2 > balance Sheet > total Current Assets
349388000
Quarters > 2 > balance Sheet > property Plant Equipment
66587000
Quarters > 2 > balance Sheet > total Assets
501715000
Quarters > 2 > balance Sheet > payables
8502000
Quarters > 2 > balance Sheet > short Term Debt
2546000
Quarters > 2 > balance Sheet > long Term Debt
8921000
Quarters > 2 > balance Sheet > total Liabilities
61409000
Quarters > 2 > balance Sheet > equity
440306000
Quarters > 2 > cash Flow > net Income
-25848000
Quarters > 2 > cash Flow > depreciation
29764000
Quarters > 2 > cash Flow > change In Working Capital
-20381000
Quarters > 2 > cash Flow > cash From Operations
-6036000
Quarters > 2 > cash Flow > capital Expenditures
4740000
Quarters > 2 > cash Flow > cash From Investing
-22431000
Quarters > 2 > cash Flow > cash From Financing
-1553000
Quarters > 2 > cash Flow > net Change In Cash
-30020000
Quarters > 2 > ratios > PE
-0.9034919081407948
Quarters > 2 > ratios > PB
2.4995985292046896
Quarters > 2 > ratios > ROE
-5.87046281449719
Quarters > 2 > ratios > ROA
-5.151928883928127
Quarters > 2 > ratios > FCF
-10776000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.12247124607901078
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
86311000
Quarters > 3 > income Statement > cost Of Revenue
16183000
Quarters > 3 > income Statement > gross Profit
70128000
Quarters > 3 > income Statement > operating Expenses
66078000
Quarters > 3 > income Statement > operating Income
4050000
Quarters > 3 > income Statement > interest Expense
92000
Quarters > 3 > income Statement > pretax Income
7885000
Quarters > 3 > income Statement > net Income
9590000
Quarters > 3 > income Statement > eps
0.3175496688741722
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
30200000
Quarters > 3 > income Statement > income Tax Expense
-1705000
Quarters > 3 > income Statement > EBITDA
13745000
Quarters > 3 > income Statement > operating Margin
4.692333538019488
Quarters > 3 > income Statement > total Other Income Expense Net
3835000
Quarters > 3 > balance Sheet > cash
119709000
Quarters > 3 > balance Sheet > short Term Investments
173421000
Quarters > 3 > balance Sheet > receivables
51218000
Quarters > 3 > balance Sheet > inventories
8135000
Quarters > 3 > balance Sheet > total Current Assets
360154000
Quarters > 3 > balance Sheet > property Plant Equipment
62706000
Quarters > 3 > balance Sheet > total Assets
531235000
Quarters > 3 > balance Sheet > payables
6901000
Quarters > 3 > balance Sheet > short Term Debt
1943000
Quarters > 3 > balance Sheet > long Term Debt
9745000
Quarters > 3 > balance Sheet > total Liabilities
75400000
Quarters > 3 > balance Sheet > equity
455835000
Quarters > 3 > cash Flow > net Income
9590000
Quarters > 3 > cash Flow > depreciation
5768000
Quarters > 3 > cash Flow > change In Working Capital
1983000
Quarters > 3 > cash Flow > cash From Operations
24365000
Quarters > 3 > cash Flow > capital Expenditures
7567000
Quarters > 3 > cash Flow > cash From Investing
5770000
Quarters > 3 > cash Flow > cash From Financing
-5385000
Quarters > 3 > cash Flow > net Change In Cash
24750000
Quarters > 3 > ratios > PE
0.3175496688741722
Quarters > 3 > ratios > PB
2.5487160924457313
Quarters > 3 > ratios > ROE
2.1038314302324306
Quarters > 3 > ratios > ROA
1.8052274417160015
Quarters > 3 > ratios > FCF
16798000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.19462177474481815
Quarters > 3 > health Score
72
Valuation > metrics > PE
-0.017232483747807243
Valuation > metrics > PB
2.394706966765586
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-0.10726994771392967
Profitability > metrics > ROA
-0.1401128173862947
Profitability > metrics > Net Margin
-0.00603301903832954
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2049905148529267
Risk > metrics > Interest Coverage
-283.5
Risk > final Score
-1074
Risk > verdict
High
Liquidity > metrics > Current Ratio
26.17635431918009
Liquidity > metrics > Quick Ratio
25.54311859443631
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
80
Prev Valuations > 2
100
Prev Profitabilities > 0
14
Prev Profitabilities > 1
0
Prev Profitabilities > 2
29
Prev Risks > 0
-750
Prev Risks > 1
-6511
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:33:54.029Z
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACastle Biosciences (CSTL) Highlights Breakthrough in Barrett's E GuruFocus
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$37.25
Analyst Picks
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Medium
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 98.21% of the total shares of Castle Biosciences Inc
1.
BlackRock Inc(10.8751%)
since
2025/06/30
2.
Vanguard Group Inc(7.4807%)
since
2025/06/30
3.
Principal Financial Group Inc(6.2016%)
since
2025/06/30
4.
Portolan Capital Management, LLC(5.135%)
since
2025/06/30
5.
Dimensional Fund Advisors, Inc.(4.7504%)
since
2025/06/30
6.
Nuveen, LLC(3.6993%)
since
2025/06/30
7.
Wasatch Advisors LP(3.6189%)
since
2025/06/30
8.
Citadel Advisors Llc(3.063%)
since
2025/06/30
9.
Principal SmallCap R5(2.861%)
since
2025/07/31
10.
Vanguard Total Stock Mkt Idx Inv(2.8491%)
since
2025/07/31
11.
BRAIDWELL LP(2.8362%)
since
2025/06/30
12.
Principal U.S. Small Cap Equity(2.6938%)
since
2025/06/30
13.
Allianz Asset Management AG(2.4605%)
since
2025/06/30
14.
State Street Corp(2.4396%)
since
2025/06/30
15.
iShares Russell 2000 ETF(2.3848%)
since
2025/08/31
16.
Geode Capital Management, LLC(2.3784%)
since
2025/06/30
17.
Renaissance Technologies Corp(2.3114%)
since
2025/06/30
18.
Schroder Investment Management Group(2.2358%)
since
2025/06/30
19.
Wasatch Ultra Growth(2.1622%)
since
2025/06/30
20.
Strategic Advisers U.S. Total Stock(2.1412%)
since
2025/07/31
21.
Palisade Capital Management LLc(1.9826%)
since
2025/06/30
22.
CREF Stock R3(1.6671%)
since
2025/07/31
23.
BlackRock Global Equity Mkt Netrl Instl(1.4966%)
since
2025/07/31
24.
Millennium Management LLC(1.4768%)
since
2025/06/30
25.
Wellington Management Company LLP(1.4038%)
since
2025/06/30
26.
Bank of America Corp(1.3194%)
since
2025/06/30
27.
Palisade Small Cap Core Equity(1.3155%)
since
2025/06/30
28.
Ameriprise Financial Inc(1.284%)
since
2025/06/30
29.
UBS Group AG(1.2543%)
since
2025/06/30
30.
Wasatch Micro Cap(1.2388%)
since
2025/06/30
31.
Schroder US Smaller Companies Acc(1.104%)
since
2025/07/31
32.
Vanguard Institutional Extnd Mkt Idx Tr(1.0722%)
since
2025/07/31
33.
Fidelity Small Cap Index(0.9849%)
since
2025/06/30
34.
Vanguard Explorer Inv(0.9511%)
since
2025/06/30
35.
DFA US Small Cap Value I(0.9408%)
since
2025/07/31
36.
iShares Russell 2000 Value ETF(0.8687%)
since
2025/08/31
37.
Buffalo Small Cap Growth(0.826%)
since
2025/06/30
38.
Kornitzer Small Cap Equity(0.826%)
since
2025/03/31
39.
Columbia Small Cap Value Discv A(0.8187%)
since
2025/07/31
40.
Columbia Small Cap Value Discovery Fund(0.7963%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.